Reflections on the cost-effectiveness of recombinant FSH in assisted reproduction. The clinician's perspective

被引：10

作者：

Balasch, J ^{[1
]}

Barri, PN ^{[1
]}

机构：

[1] Univ Barcelona, Inst Clin Gynecol Obstet & Neonatol, Hosp Clin, Fac Med,Inst Invest Biomed August Pi i Sunyer, Barcelona 08036, Spain

来源：

JOURNAL OF ASSISTED REPRODUCTION AND GENETICS | 2001年 / 18卷 / 02期

关键词：

assisted reproduction; recombinant follicle stimulating hormone; cost effectiveness;

D O I：

10.1023/A:1026501821849

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Purpose: To analyze the relative cost-effectiveness of recombinant FSH (rFSH) and urinary FSH (uFSH) in assisted reproduction techniques (ART). Methods: Calculation of the average cost-effectiveness ratio and the incremental cost-effectiveness ratio to compare costs and effects (pregnancy rates) of the two therapeutic options (rFSH and uFSH). Results: Assuming that the cost of the procedure per ART cycle is between 100, 000 pesetas (601 euro) and 150, 000 pesetas (901.52 euro), and pricing the GnRH analogues used Soi pituitary suppression at 35,000 pesetas (210.3 euro), the cost-effectiveness ratio is better for rFSH than for uFSH, implying that the cost per pregnancy is lower when the recombinant preparation is used. Conclusions: In ART the use of rFSH is more cost-effective than uFSH.

引用

页码：45 / 55

页数：11

共 40 条

[1] Recombinant follicle-stimulating hormone in the treatment of patients with history of severe ovarian hyperstimulation syndrome [J].